Infectiology

Vaborem®

Vaborem® is the first boron-based beta-lactamase inhibitor of its class, with activity against serine beta-lactamases, which is particularly optimized for potent inhibition of KPC.3

Vaborem® is indicated for the treatment of the following infections in adults:

  • Complicated urinary tract infection (cUTI) including pyelonephritis
  • Complicated intra-abdominal infection (cIAI)
  • Nosocomial-acquired pneumonia (HAP: hospital-acquired pneumonia) including ventilator-associated pneumonia (VAP: ventilator pneumonia)

Treatment of patients with bacteremia associated or suspected to be associated with any of the above infections.

Vaborem® is also indicated for the treatment of infections caused by aerobic Gram-negative organisms in adults with limited treatment options.1

Vaborem® is characterized by inhibitory activity against Klebsiella pneumoniae carbapenemase (KPC), a common cause of resistance of enterobacteria to carbapenems (CRE).2

Treatment of CRE with Vaborem® demonstrated increased clinical efficacy in Tango II, a Phase III study conducted in 77 patients with confirmed/suspected CRE infection. Treatment of CRE with Vaborem® monotherapy demonstrated improved clinical cure, reduced mortality and decreased nephrotoxicity compared to best available therapy.3,4

Indeed, CRE-lnfections represent an enormous burden on patients' lives and healthcare resource consumption, with a very high mortality rate of up to 75%.

CRE-lnfections are difficult to treat because they are resistant to the class of beta-lactam antibiotics, which includes the carbapenems used as a last resort against resistant infections. In addition, these pathogens often exhibit multiple resistance mechanisms to other classes of antibiotics, resulting in multidrug-resistant organisms with few effective treatment options.

Carbapenemase enzymes have a global distribution, but there is considerable variability at continental and regional levels and even from hospital to hospital. Among the various carbapenemase enzymes, the KPC family has the greatest global distribution and is endemic in some countries such as Italy and Greece. Awareness of the presence of specific resistance mechanisms, including carbapenem resistance, is critical for preventing their spread and selecting appropriate treatments.

References: 1 VABOREM® Fachinformation, 2 Aures 2017, 3 Wunderink lnfect Dis Ther 2018;7:439-455, 4.Bassetti M, et al.,: A Post Hoc Analysis Adv Ther 2019 May 16.

AT-WEB-16-10-2021

menarini-austria-vaborem


Vaborem® is available in the following package sizes and dosages:
6 vials - 1 g/1 g


Dear visitor, the gender form selected on our homepage always refers to female, male and various people at the same time. We have refrained from using a gender-specific spelling or multiple designations solely for the purpose of better readability. All personal designations are to be understood as gender-neutral.

Liebe Besucherin, lieber Besucher, die auf unserer Homepage gewählte Geschlechtsform bezieht sich immer zugleich auf weibliche, männliche und diverse Personen. Wir haben ausschließlich zum Zweck der besseren Lesbarkeit auf eine geschlechtsspezifische Schreibweise bzw. auf eine Mehrfachbezeichnung verzichtet. Alle personenbezogenen Bezeichnungen sind geschlechtsneutral zu verstehen.

A. Menarini Pharma Gesellschaft mit beschränkter Haftung
Firmenbuchnummer: FN 177062k
Firmenbuchgericht: Handelsgericht Wien
UID-Nummer: ATU 46203601

A. Menarini Pharma limited liability company
Commercial register number: FN 177062k
Commercial register court: Commercial Court Vienna
VAT-Number: ATU 46203601

© 2024 Menarini Austria - All rights reserved